Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes (Q80146188)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428517%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428517%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

5

Victoria Polonis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428517%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

7

Per Johan Klasse

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428517%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

8

John P Moore

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428517%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Thomas J Ketas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428517%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Susan M Schader

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428517%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Juan Zurita

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428517%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Esther Teo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428517%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Min Lu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428517%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

10 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428517%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

364

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428517%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428517%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

431-440

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428517%20AND%20SRC:MED&resulttype=core&format=json

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Molecular and Clinical Epidemiology of CXCR4‐Using HIV‐1 in a Large Population of Antiretroviral‐Naive Individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Antibody and virus: binding and neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

HIV vaccine design and the neutralizing antibody problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

The HIV Env-mediated fusion reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Perils at mucosal front lines for HIV and SIV and their hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Entry Inhibitors SCH-C, RANTES, and T-20 Block HIV Type 1 Replication in Multiple Cell Types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Occupancy and mechanism in antibody-mediated neutralization of animal viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Which topical microbicides for blocking HIV-1 transmission will work in the real world?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Microbicides and other topical strategies to prevent vaginal transmission of HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Global epidemiology of HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Urgently needed: a filter for the HIV-1 vaccine pipeline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Resistance to HIV-1 entry inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Inhibiting sexual transmission of HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Immune control of HIV: the obstacles of HLA and viral diversity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

inferred from DOI database lookup

7 January 2021

based on heuristic

Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

inferred from DOI database lookup

7 January 2021

based on heuristic

Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.03.001

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2007.03.001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17428517%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference